Merck net sales rose 8.9%Christian Fernsby ▼ | March 5, 2020
At €16.2 billion, Merck group net sales rose in 2019 8.9% in comparison with 2018.
Merck Rising 15.4% to €4.4 billion, EBITDA pre
Additionally, there were positive foreign exchange effects of 2.1% and a portfolio-related increase of 1.4%1 .
Rising 15.4% to €4.4 billion, EBITDA pre, the most important financial indicator to steer operating business, advanced more strongly than sales.
The EBITDA pre margin rose to 27.1%.
Merck thus grew profitably in 2019.
The operating result (EBIT) advanced 22.8% to €2.1 billion.
The -60.9% decline in Group net income to €1.3 billion was attributable to a one-time effect, namely the gain on the sale of the Consumer Health business in the previous year.
Net financial debt rose particularly as a result of the acquisition of Versum from €6.7 billion at the end of 2018 to €12.4 billion as of year-end 2019.
Earnings per share pre, which is a determinant of the Merck dividend, grew 9% to €5.56 in 2019.
In line with the company’s sustainable dividend policy, the Executive Board and the Supervisory Board will therefore propose a dividend of €1.30 per share, an increase of €0.05 over the previous year. ■